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Abstract
Introduction: To assess the usefulness of circulating IL-16 and RANTES measurements as markers of Graves’ orbitopathy (GO) activity 
and to estimate the role of these cytokines in GO pathogenesis.
Material and methods: 42 individuals were divided into four groups: Group 1 comprised 15 euthyroid patients with clinical symptoms of GO 
who underwent corticosteroid therapy consisting of intravenous infusions of methylprednisolone (MP) and teleradiotherapy (TR); Group 2 
comprised ten patients with hyperthyroid GD (Gtx); Group 3 comprised ten patients with GD in euthyreosis (Geu); and Group 4 comprised 
seven healthy volunteers age- and sex-matched to Groups 1–3. Serum samples were collected 24 hours before the first dose of MP, 24 hours after 
the first dose of MP, before TR, and at the end of therapy. Serum IL-16 and RANTES were determined by ELISA and TSH-Rab by RIA.
Results: Serum IL-16 levels in patients with GO were significantly elevated at the end of therapy: 346 pg/mL (257–538) compared to IL-16 
values before treatment: 250 ng/mL (211–337) and to the control group. RANTES serum concentrations did not significantly differ between 
studied groups, and immunosuppressive treatment did not influence its level. A negative correlation between TSH-Rab and RANTES was 
found in all studied groups (R = –0.32, p < 0.01).
Conclusions: Our data suggests that IL-16 may exert an immunoregulatory effect in Graves’ orbitopathy. Serum measurements of both 
IL-16 and RANTES may be clinically useful; however, establishing their place in the diagnostics and treatment monitoring of GO needs 
further research. (Pol J Endocrinol 2012; 63 (2): 92–96)
Key words: cytokines, chemokines, TSH-Rab, Graves’ disease, orbitopathy
Streszczenie
Wstęp: Ocena przydatności oznaczania krążącej IL-16 i RANTES jako wskaźników aktywności GO oraz określenie roli tych cytokin 
w patogenezie GO.
Materiał i metody: 42 osoby w 4 grupach: 1 — 15 pacjentów z klinicznymi objawami orbitopatii w eutyreozie (GO), którzy poddali się 
leczeniu kortykosteroidami przy zastosowaniu podawanego dożylnie metylprednizolonu (MP) i teleradioterapii (TR); 2 — 10 pacjentów 
z chorobą Gravesa w nadczynności (Gtx); 3 — 10 pacjentów z chorobą Gravesa w eutyreozie (Geu); 4 — 7 zdrowych ochotników dobranych 
pod względem płci i wieku do grup 1.–3. Próbki krwi pobrano 24 h przed MP, 24 h po 1. dawce MP, przed TR i po zakończeniu leczenia. 
Stężenia IL-16 i RANTES w surowicy oznaczono metodą ELISA, a TSH-Rab — metodą RIA.
Wyniki: Stężenie IL-16 w surowicy u pacjentów z GO było istotnie wyższe po zakończeniu terapii — 346 pg/ml (257–538) w porównaniu 
z wartością IL-16 przed leczeniem — 250 ng/ml (211–337) i w odniesieniu do grupy kontrolnej. Stężenie RANTES w surowicy nie różniło 
się istotnie między badanymi grupami i leczenie immunosupresyjne nie wpłynęło na jej wartość. Wykazano ujemną korelację między 
TSH-Rab i RANTES we wszystkich badanych grupach (R = –0,32; p < 0,01).
Wnioski: Uzyskane dane wskazują, że IL-16 może wywierać immunomodulujący wpływ na przebieg orbitopatii. Zarówno oznaczenia 
IL-16, jak i RANTES w surowicy mogą być przydatne klinicznie, jednak ustalenie ich miejsca w diagnostyce i monitorowaniu leczenia GO 
wymaga dalszych badań. (Endokrynol Pol 2012; 63 (2): 92–96)
Słowa kluczowe: cytokiny, chemokiny, TSH-Rab, choroba Gravesa, orbitopatia
Introduction
Graves’ orbitopathy (GO) is the most challenging clini-
cal problem in the treatment of the common but poorly 
understood autoimmune syndrome, Graves’ disease 
(GD). In the pathogenesis of GD, involving both thyroid 
and orbital connective tissue, a crucial role is attributed 
to thyrotropin receptor (TSH-R) as a main autoantigen 
[1, 2]. The presence of circulating antibodies against 
TSH-R (TSH-Rab) is a characteristic feature of GO and 
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a positive correlation has been found between TSH-Rab 
and the activity of GO [3, 4].
However, another autoantigen, namely insulin-like 
growth factor 1 receptor (IGF-1R), has been recently 
shown to play an important role in GO development. 
Immunoglobulins γ of patients with Graves’ disease 
can induce orbital fibroblasts from patients with GO to 
produce hyaluronan and to up-regulate the synthesis of 
interleukin-16 (IL-16) and RANTES [5,6]. These effects 
are absent in fibroblasts from normal controls and are 
mediated through IGF-1R [7].
Interleukin-16 is a pleiotropic cytokine that is a natu-
ral ligand of CD4 [8]. It is a known chemoattractant for 
CD4+ T cells, monocytes, eosinophils and dendritic 
cells, with preferential chemoattractant activity for the 
Th1 subset of CD4+ T cells [9]. IL-16 has been shown 
to induce the high affinity IL-2R receptor (CD25) on 
CD4+ T cells that imparts responsiveness to IL-2 [10].
Regulated upon activation normal T cell expressed 
and secreted, also known as CCL5 (RANTES), was origi-
nally recognised as a product of activated T cells [11]. 
Now widely established as an inflammatory chemokine, 
CCL5 mediates chemotactic activity in T cells, mono-
cytes, dendritic cells, natural killer cells, eosinophils, and 
basophils [12]. High serum concentrations of CCL5 have 
been associated with rapid progression of radiographic 
changes in rheumatoid arthritis [13].
Severe GO requires intensive treatment with immu-
nosuppressive medication, most often by corticosteroids 
(CS) and teleradiotherapy (TR) [14]. However, the ef-
ficacy of both CS and TR is limited, and their use entails 
considerable risk. There have been many attempts to 
find reliable predictors of response to immunosup-
pressive treatment, but very few have proved useful 
in clinical practice.
Thus the aim of this study was to assess the useful-
ness of circulating IL-16 and RANTES measurements as 
markers of GO activity, and to assess the role of these 
cytokines and IGF-1R in GO pathogenesis.
Material and methods
The study was carried out in 42 individuals divided 
into four groups.
Group 1 (the GO group) comprised 15 GD patients 
with clinical symptoms of orbitopathy (ten females and 
five males, mean age 48 ± 12 years). Clinical features of 
subjects included in the study are shown in Table I. All 
these patients were euthyroid with thiamazol (patients 1, 
3, 5, 9, 10, 11), levothyroxine (patients 4, 7, 12) or without 
treatment (patients 2, 6, 8, 13, 14, 15). In all patients, 7-item 
Clinical Activity Score of eye changes (CAS) was ≥ 3 and an-
amnesis of GO ≤ 1 year. All of them underwent 12 weeks of 
corticosteroid therapy consisting of intravenous infusions 
of methylprednisolone (MP): 6 × 500 milligrams and sub-
sequently 6 × 250 milligrams. In the period of minor MP 
dose administration, teleradiotherapy (TR) (ten fractions of 
1 Gy per day) was used in ten individuals (patients 6–15) 
with high activity of inflammation assessed in Magnetic 
Resonance Imaging (MRI). The serum samples were col-
lected 24 hours before the first dose of MP, 24 hours after 
the first dose of MP, before TR (after the 6th dose of MP), 
and at the end of therapy.
Group 2 (the Gtx group) comprised ten patients with 
hyperthyroid untreated Graves’ disease without GO 
symptoms: eight females and two males aged 54 ± 14 
years with duration of the disease from 3–12 months. Thy-
rotoxicosis was confirmed with TSH, free thyroxin and 
triiodothyronin serum concentration measurement.
Group 3 (the Geu group) comprised ten patients 
with Graves’ disease without GO symptoms in eu-
thyreosis (at least three months) treated with thiamazol: 
seven females and three males, mean age 48 ± 18 years 
with a duration of the disease from 7–18 months.
Group 4 (the Ctrl group) comprised seven healthy 
volunteers age- and sex-matched to Groups 1–3: five 
females and two males aged 48 ± 13 years who had 
no family history of Graves’ disease or of any other 
autoimmune disease.
Clinical euthyreosis in Groups 1 and 3 was con-
firmed by thyrotropin, free thyroxine and free triiodo-
thyronin estimation. No acute infections were observed 
in patients three weeks prior to the study.
All the sera were kept frozen at –70°C until used. 
ELISA commercial kits were used to determine serum 
levels of IL-16 and RANTES (Quantikine, R&D Systems, 
Minneapolis, MN, USA; sensitivity respectively 6.2 pg/ 
/mL and 2.0 pg/mL; intra-assay coefficient of variation 
[CV] 4.8% and 2.4%). The serum levels of thyrotropin 
receptor antibodies (TSHRab) were determined by 
the RIA method (TRAK kit, Brahms, Berlin, Germany; 
sensitivity 0.3 IU/L; CV 7.0%).
The statistical significance was estimated by 
Mann-Whitney test. To evaluate relationships between 
variables, Spearman’s test was performed using Statis-
tica v. 9.0 for Windows XP (StatSoft, Tulsa, OK, USA).
Results
Figure 1 shows medians, interquartile and total ranges 
of IL-16 (in pg/mL). In the Ctrl group, IL-16 median 
was 280 pg/mL, in the Geu group, it was 302, in the Gtx 
group, it was 244, and in the GO group before treatment, 
it was 250. In GO 24 hours after the first dose of MP 
(GO1), it was 311, in GO after the 6th dose of MP (GO2), 
it was 348, and in GO at the end of therapy (GO3), it 
was 346 pg/mL. We found statistical significance in IL-
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between IL-16 values in GO patients at the end of therapy 
(GO3) and basal values in this group (GO) (p < 0.05).
RANTES (in ng/mL) medians, interquartile and total 
ranges in the controls were 106 (65 [75–133] 160); in the 
Geu group they were 80 (47 [59–97] 125); in the Gtx 
group they were 67 (35 [55–92] 94); in the GO group 
before treatment they were 69 (27 [51–89] 119); in the 
GO group 24 hours after the first dose of MP (GO1) 
they were 74 (43 [64–86] 108); in the GO group after 
the 6th dose of MP (GO2) they were 81 (44 [47–96] 125); 
and in the GO group at the end of therapy (GO3) they 
were 80 (30 [54–115] 152). No statistical significance 
was found in RANTES serum concentrations between 
the studied groups, and immunosuppressive therapy 
in GO patients did not influence its value significantly.
Figure 2 shows medians, interquartile and total 
ranges of TSH-Rab (in IU/L). In the Ctrl group TSH-Rab 
median was 0.5 IU/L; in the Geu group it was 2.3; in the 
Gtx group it was 5.5; in the GO group before treatment 
it was 4.4; in the GO group 24 hours after the first dose 
of MP (GO1) it was 5.3; in the GO group after the 6th 
dose of MP (GO2) it was 3.8; and in the GO group at 
the end of therapy (GO3) it was 1.9. We found statisti-
cally significant differences in TSH-Rab values between 
Geu, Gtx and GO compared to Ctrl (for all relationships 
p < 0.001) and between TSH-Rab values in the GO 
group at the end of therapy (GO3) and basal values in 
this group (GO) (p < 0.05).
Table I. Clinical features of studied patients with Graves’ orbitopathy
Tabela I. Kliniczne cechy pacjentów z orbitopatią Gravesa poddanych analizie








CAS GO activity after 
therapy (MRI)
1 51 m NJ 1 – – Current 4 Æ 1 –
2 25 m MP 8 – – Current 3 Æ 1 –
3 50 f WB 3 – – Current 3 Æ 0 –
4 52 f TA 3 – 24 Current 3 Æ 1 –
5 48 f ZM 8 – – Current 3 Æ 0 –
6 36 f KE 4 – – No 3 Æ 1 –
7 76 m WT 2 – 8 No 3 Æ 1 –
8 60 f LH 6 11 – Current 4 Æ 1 –
9 50 f PB 6 – – Current 3 Æ 0 –
10 50 m SD 12 – – Current 3 Æ 1 –
11 30 f SK 3 – 6 Current 3 Æ 2 +
12 49 f JJ 2 – 84 Current 4 Æ 1 +
13 41 f SG 4 – – Current 4 Æ 2 +
14 52 f CK 6 – 24 Current 3 Æ 0 +
15 51 f WK 3 – – Current 3 Æ 1 +
aPeriod before GO treatment
Figure 1. Medians, interquartile and total ranges of IL-16 (in 
pg/mL) in the control group (n = 7), in patients with euthyroid 
Graves’ disease (n = 10), in thyrotoxic Graves’ patients (n = 10), 
and in individuals with Graves’ orbitopathy (n = 15) before the 
treatment, after first methylprednisolone dose (GO1), after the 6th 
methylprednisolone dose (GO2), and at the end of therapy (GO3)
Rycina 1. Mediany, zakres kwartylowy i całkowity wartości IL-16 
(w pg/ml) w grupie kontrolnej (n = 7), u pacjentów z chorobą 
Gravesa w eutyreozie (n = 10), u pacjentów z chorobą Gravesa 
w nadczynności tarczycy (n = 10) i u osób z orbitopatią Gravesa 
(n = 15) przed leczeniem, po 1. dawce metylprednizolonu (GO1), po 
6. dawce metylpredizolonu (GO2) i po zakończeniu terapii (GO3)
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The results of serum IL-16, RANTES (in ng/mL) and 
TSH-Rab in GO patients who responded to the therapy 
(no activity signs in MRI after treatment) (n = 10) and 
non-responders (signs of activity in MRI after treatment) 
(n = 5) did not differ significantly.
We found a negative correlation between RANTES 
(in ng/mL) and TSH-Rab (IU/L) (Figure 3).
Discussion
In our previous study, we showed the importance of 
CD40/CD40L interaction in GO development [15]. Data 
from our present study suggests that IL-16, a chemokine 
secreted in consequence of signal transduction via the 
CD40/CD40L pathway, may exert immunoregulatory 
properties in the autoimmune process in patients with 
GO. Immunosuppressive therapy with corticosteroids 
and teleradiotherapy led to a significant increase in se-
rum IL-16. Recent studies suggest that the presence of 
IL-16 may contribute to the recruitment and induction 
of the peripheral expansion of CD4+ immunoregula-
tory T (Treg) cells at sites of inflammation [16]. Treg 
cells have been classified into three major groups: 
CD4+CD25+ cells, Tr1 cells, and Th3 cells [17]. These 
cells are distinct in terms of cytokine production and 
suppressive function. CD4+CD25+ cells generated 
in the thymus, also termed ‘natural Treg cells’, secrete 
both IL-10 and TGFß and have been shown by in vitro 
studies to be suppressive through cell-cell contact [18]. 
IL-16 has been recently shown to have chemoattractant 
activity for a T cell CD25+CTLA-4+FoxP3+ subpopula-
tion, and is capable of suppressing the proliferation and 
production of Th2 cytokines of autologous T cells [16].
This is consistent with previous reports demonstrat-
ing the preferential effect of IL-16 on Th1 cell migra-
tion and the selective inhibition of Th2 cytokines [19]. 
Interestingly the diseases in which anti-IL-16 antibod-
ies treatment is beneficial are generally classified as 
Th1-mediated, whereas IL-16 treatment is beneficial in 
Th2-mediated diseases. Recent data suggests the poten-
tial of IL-16 to recruit CD4+ T cells that are primarily 
Th1, including a preferential effect on Treg cells that 
have the ability to inhibit Th2 cell activation without 
affecting Th1 cell activity. We have not found significant 
alterations in RANTES serum concentrations during im-
munosuppressive therapy in GO patients, but, based on 
a negative correlation between RANTES and TSH-Rab, 
it could be speculated that, similarly to IL-16, RANTES 
may chemoattract Treg as immunomodulating factors.
TSH-Rab measurement has been found to be useful as 
a marker of GO activity and as a predictor of relapse in the 
treatment of Graves’ hyperthyroidism [3, 4]. Our present 
TSH-Rab measurements are in line in these findings: we 
observed a gradual decrease of TSH-Rab concentration 
during immunosuppressive therapy. These clinical ob-
servations make the hypothesis of a pivotal role of TSH-R 
very attractive, although direct evidence is lacking. IGF-1R 
may be another important autoantigen in GO. Tsui et al. 
Figure 2. Medians, interquartile and total ranges of TSH-Rab 
(in IU/L) in the control group (n = 7), in patients with euthyroid 
Graves’ disease (n = 10), in thyrotoxic Graves’ patients (n = 10), 
and in individuals with Graves’ orbitopathy (n = 15) before the 
treatment, after first methylprednisolone dose (GO1), after the 6th 
methylprednisolone dose (GO2), and at the end of therapy (GO3)
Rycina 2. Mediany, zakres kwartylowy i całkowity wartości TSH- 
-Rab (w IU/l) w grupie kontrolnej (n = 7), u pacjentów z chorobą 
Gravesa w eutyreozie (n = 10), u pacjentów z chorobą Gravesa 
w nadczynności tarczycy (n = 10) i u osób z orbitopatią Gravesa 
(n = 15) przed leczeniem, po 1. dawce metylprednizolonu (GO1), po 
6. dawce metylpredizolonu (GO2) i po zakończeniu terapii (GO3)
Figure 3. Negative correlation between TSH-Rab (IU/l) and 
RANTES (ng/mL) in all studied groups (R = –0.32, p < 0.01)
Rycina 3. Ujemna korelacja pomiędzy TSH-Rab (IU/l) i RANTES 
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suggested physical and functional relationships between 
IGF-1R and TSH-R based on colocalisation studies and the 
finding that monoclonal antibodies specifically blocking 
IGF-1R inhibit thyrotropin-induced kinase signalling [20]. 
Orbital fibroblasts in GO patients express higher levels of 
IGF-1R than normal fibroblasts [5]. Moreover, stimula-
tion of orbital fibroblasts from GO patients to synthesise 
IL-16 and RANTES-chemoattractants of CD4+ cells by 
immunoglobulins g fraction of serum samples obtained 
from GD patients has been shown to be mediated by 
IGF-1R- dependent pathway [6, 7].
In our study, IL-16 and RANTES serum concentra-
tions were not elevated in GO patients compared to 
other groups.
Summary
In summary, our data suggests that IL-16 may exert 
an immunoregulatory influence in Graves’ orbitopathy. 
Assessing the clinical usefulness of IL-16 and RANTES 
measurements, and defining the role of these cytokines 
and IGF-1 receptor in the pathogenesis of Graves’ or-
bitopathy, needs further research.
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